Mechanism of action of and resistance to quinolones

• Published in: Microbial biotechnology Vol. 2; no. 1; pp. 40 - 61
• Main Authors: Fàbrega, Anna, Madurga, Sergi, Giralt, Ernest, Vila, Jordi
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-01-2009; John Wiley & Sons, Inc
• Subjects: Anti-Bacterial Agents - metabolism; Anti-Bacterial Agents - pharmacology; Antibacterial agents; Bacteria; Bacteria - drug effects; Bacteria - genetics; Bacteria - metabolism; Bacterial infections; Bacterial Proteins - genetics; Bacterial Proteins - metabolism; Cell division; Chromosomes; Deoxyribonucleic acid; DNA; DNA topoisomerase; DNA topoisomerase IV; Drug Resistance, Bacterial; Drugs; E coli; Efflux; Enzymes; Fluoroquinolones; Gene Expression Regulation, Bacterial; Genes; Level (quantity); Mutation; Nalidixic acid; Organic chemistry; Plasmids; Protein Binding; Quinolones; Quinolones - metabolism; Quinolones - pharmacology; Review; Rings (mathematics); RNA polymerase; Urinary tract diseases; Urinary tract infections; Urogenital system; Viability
• ISSN: 1751-7915; 1751-7915
• DOI: 10.1111/j.1751-7915.2008.00063.x

Summary
Fluoroquinolones are an important class of wide‐spectrum antibacterial agents. The first quinolone described was nalidixic acid, which showed a narrow spectrum of activity. The evolution of quinolones to more potent molecules was based on changes at positions 1, 6, 7 and 8 of the chemical structure of nalidixic acid. Quinolones inhibit DNA gyrase and topoisomerase IV activities, two enzymes essential for bacteria viability. The acquisition of quinolone resistance is frequently related to (i) chromosomal mutations such as those in the genes encoding the A and B subunits of the protein targets (gyrA, gyrB, parC and parE), or mutations causing reduced drug accumulation, either by a decreased uptake or by an increased efflux, and (ii) quinolone resistance genes associated with plasmids have been also described, i.e. the qnr gene that encodes a pentapeptide, which blocks the action of quinolones on the DNA gyrase and topoisomerase IV; the aac(6′)‐Ib‐cr gene that encodes an acetylase that modifies the amino group of the piperazin ring of the fluoroquinolones and efflux pump encoded by the qepA gene that decreases intracellular drug levels. These plasmid‐mediated mechanisms of resistance confer low levels of resistance but provide a favourable background in which selection of additional chromosomally encoded quinolone resistance mechanisms can occur.